bioAffinity Technologies (BIAF)

The company’s lead commercial test is CyPath Lung, a diagnostic assay designed to help detect early-stage lung cancer. The test analyzes cells collected from a patient sample and looks for cancer-related cellular patterns that may indicate malignancy in the lung. Early lung cancer detection is a significant clinical challenge because symptoms often appear late, while earlier identification can improve the range of treatment options available to patients.

bioAffinity is also applying its platform beyond cancer detection. The company is developing noninvasive precision diagnostic tests intended to help identify patients with asthma and chronic obstructive pulmonary disease who may benefit from emerging or targeted therapies. This reflects a broader strategy of using cellular analysis to support more personalised respiratory care.

The business is organised into two operating segments: Diagnostic Research and Development and Laboratory Services. Research and development supports the advancement of its testing platform and future assays, while laboratory services relate to the operational delivery of diagnostic testing.

For investors, BIAF represents exposure to a specialised medical diagnostics company operating at the intersection of lung health, laboratory testing, artificial intelligence and precision medicine. Its prospects depend on clinical adoption, reimbursement pathways, regulatory and laboratory execution, and the ability to demonstrate practical value for physicians, patients and healthcare systems.